TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06549049

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TranS-C for PTSD
Description: The Transdiagnostic sleep and circadian intervention (TranS-C), developed by Allison Harvey, Ph.D. and Daniel Buysse, M.D., involves a patient-centered, module-based, flexibly structured approach that tackles numerous sleep disturbances using evidence-based strategies with the goal of improving sleep and related impairments in daytime functioning. It is thus well-suited for tackling sleep disturbances and the associated impairments in social, occupational and overall functioning in veterans with PTSD. The proposed study is a randomized, controlled clinical trial examining the effectiveness of a modified TranS-C intervention for veterans with PTSD. The modified approach, TranS-C for PTSD (TSC-PTSD), elevates the importance of nightmare-focused, apnea-focused, and insomnia-focused modules relative to the standard intervention, incorporates an evidence-based relaxation module, and modifies the nightmare and apnea modules based on strategies used for veterans in the VA healthcare system.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Psychoeducation Control
Description: Participants will receive psychoeducation about sleep.
Study: NCT04275310

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Microeconomic Intervention
Description: The intervention will consist of six sessions on six different days. Sessions will be held at VCU or at one of VCU's community partners. Each session will last for around 2 ½ hours (around 15 hours total). There will be breaks and food will be provided. During the sessions the facilitators will provide education on a variety of topics, including economic services that are available to people living in Richmond, job skills (such as creating a resume and dealing with discrimination at work), personal finance education, gender transition ideas, and HIV prevention. The sessions will occur in a group of about 4-10 transgender women.
Study: NCT04914416

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T12
Description: Verum T12 is a polyphenol mix extract ( olive leaf, pomelo, pomegranate, and blackcurrant extract). Daily dosage is 600 mg in 3 capsules
Study: NCT04838912

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cool Kids (Chilled) Anxiety program adapted to children and youths with autism and anxiety disorders.
Description: CBT program for anxiety in teenagers with autism
Study: NCT06439914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [89Zr]Zr-DFO-emapalumab
Description: Radiotracer \[89Zr\]Zr-DFO-emapalumab administration followed by 3 PET Scans (day 0, day 1 and day 3-5) within 14 days of starting immunotherapy and repeated once 25-45 days after immunotherapy started
Study: NCT04914416

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T12
Description: Verum T12 is a polyphenol mix extract ( olive leaf, pomelo, pomegranate, and blackcurrant extract). Daily dosage is 600 mg in 3 capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T12
Description: Verum T12 is a polyphenol mix extract ( olive leaf, pomelo, pomegranate, and blackcurrant extract). Daily dosage is 600 mg in 3 capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T12
Description: Verum T12 is a polyphenol mix extract ( olive leaf, pomelo, pomegranate, and blackcurrant extract). Daily dosage is 600 mg in 3 capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Verum T12
Description: Verum T12 is a polyphenol mix extract ( olive leaf, pomelo, pomegranate, and blackcurrant extract). Daily dosage is 600 mg in 3 capsules
Study: NCT05282706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lavender Oil
Description: A hydrogel lavender oil infused aromatherapy patch

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mandarin Oil
Description: A hydrogel mandarin oil infused aromatherapy patch

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peppermint oil
Description: A hydrogel peppermint oil infused aromatherapy patch

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo patch containing no aromatherapy oil
Study: NCT06128941

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Repeated sprint
Description: * Duration of the study: 8 weeks of participation.~* Each repeated sprint training protocol: 2 training sessions per week for 4 weeks.~* Collection sessions: 3 collection sessions will be carried out: before the start of the training protocol - T0; at the end of the protocol, in week 4 - T1; and late, 4 weeks after the end of the protocol, in week 8 - T2.~* Training sessions: will be carried out on an ergometer and will consist of 3 sets of 5 sprints of 10s all-out with 20s of rest between sprints, and 5 minutes of rest between sets.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Repeated sprint
Description: * Duration of the study: 8 weeks of participation.~* Each repeated sprint training protocol: 2 training sessions per week for 4 weeks.~* Collection sessions: 3 collection sessions will be carried out: before the start of the training protocol - T0; at the end of the protocol, in week 4 - T1; and late, 4 weeks after the end of the protocol, in week 8 - T2.~* Training sessions: will be carried out on an ergometer and will consist of 3 sets of 5 sprints of 10s all-out with 20s of rest between sprints, and 5 minutes of rest between sets.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Repeated sprint
Description: * Duration of the study: 8 weeks of participation.~* Each repeated sprint training protocol: 2 training sessions per week for 4 weeks.~* Collection sessions: 3 collection sessions will be carried out: before the start of the training protocol - T0; at the end of the protocol, in week 4 - T1; and late, 4 weeks after the end of the protocol, in week 8 - T2.~* Training sessions: will be carried out on an ergometer and will consist of 3 sets of 5 sprints of 10s all-out with 20s of rest between sprints, and 5 minutes of rest between sets.
Study: NCT06214520

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App-based Motivational Interviewing & Human health coaching
Description: Patients in the intervention arm will be given a smartwatch wearable device and will be encouraged to wear it for at least 10 hours per day. Patient's daily activities such as number of steps taken, sedentary time, heart rate, sleep time and exercise will be captured and synced to the EMPOWER+ app for real-time tracking.~App-based Motivational Interviewing \& Human health coaching:~The health coach will conduct 1:1 or group-based health coaching as appropriate virtually over the EMPOWER+ app, videoconferencing platform or telephone call.
Study: NCT06214520

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Empower+ App & Smartwatch wearable tracker
Description: Patients in the intervention arm will be given a smartwatch wearable device and will be encouraged to wear it for at least 10 hours per day. Patient's daily activities such as number of steps taken, sedentary time, heart rate, sleep time and exercise will be captured and synced to the EMPOWER+ app for real-time tracking.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Empower+ App & Smartwatch wearable tracker
Description: Patients in the intervention arm will be given a smartwatch wearable device and will be encouraged to wear it for at least 10 hours per day. Patient's daily activities such as number of steps taken, sedentary time, heart rate, sleep time and exercise will be captured and synced to the EMPOWER+ app for real-time tracking.
Study: NCT04914416

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T15
Description: Verum T15 is a polyphenol mix extract ( olive leaf, pomelo, pomegranate, and/or blackcurrant extract) with white kidney bean extract, Zinc, and, black currant leaf extracts. Daily dosage is 1000 mg in 3 capsules.
Study: NCT06190977

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Otago Exercise Program
Description: Exercises will include Intensity: 10 repetitions of each set for the first two weeks and 15 repetitions of each set for the last two weeks, Frequency 3 sessions per week for 4 weeks. Time= 40-45 minutes

Intervention type: OTHER
Group type: OTHER
Intervention: General TKR pprotocol
Description: Exercises will include Intensity: 10 repetitions of each set, Frequency 5 sessions per week for 4 weeks. Time= 30 minutes
Study: NCT05138094

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally invasive simultaneous resection
Description: One minimally invasive surgical procedure wherein both the primary colorectal carcinoma and the liver metastases are removed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Minimally invasive two-stage resection
Description: Two minimally invasive surgical procedures wherein the primary colorectal carcinoma and the liver metastases are removed
Study: NCT04653064

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Placebo Cream
Description: Approximately 1 teaspoon of exfoliating skin scrub delivered approximately 5 minutes prior to pain tasks will coincide with verbal descriptors of the cream as being analgesic.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Placebo Cream
Description: Approximately 1 teaspoon of exfoliating skin scrub delivered approximately 5 minutes prior to pain tasks will coincide with verbal descriptors of the cream as being analgesic.
Study: NCT06123195

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Constipation treatment
Description: Lactulose 15 mL (10 g) will be taken orally once daily (in the evening), which can be titrated at 1-week intervals in 15 mL (10 g) increments or decrements up to 60 mL (40 g) as a total daily dose.
Study: NCT05323149

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Giving saline (loading dose of 1gm of saline 0.9%, followed by a 1gm of maintenance saline dose over 8 hours for 48 h).
Study: NCT04914416

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T15
Description: Verum T15 is a polyphenol mix extract ( olive leaf, pomelo, pomegranate, and/or blackcurrant extract) with white kidney bean extract, Zinc, and, black currant leaf extracts. Daily dosage is 1000 mg in 3 capsules.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T15
Description: Verum T15 is a polyphenol mix extract ( olive leaf, pomelo, pomegranate, and/or blackcurrant extract) with white kidney bean extract, Zinc, and, black currant leaf extracts. Daily dosage is 1000 mg in 3 capsules.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Verum T15
Description: Verum T15 is a polyphenol mix extract ( olive leaf, pomelo, pomegranate, and/or blackcurrant extract) with white kidney bean extract, Zinc, and, black currant leaf extracts. Daily dosage is 1000 mg in 3 capsules.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T15
Description: Verum T15 is a polyphenol mix extract ( olive leaf, pomelo, pomegranate, and/or blackcurrant extract) with white kidney bean extract, Zinc, and, black currant leaf extracts. Daily dosage is 1000 mg in 3 capsules.
Study: NCT05323149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: Giving TXA (loading dose of 1gm of TXA, followed by a 1gm of maintenance dose over 8 hours for 48 h).
Study: NCT06627556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H021
Description: H021 oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H021
Description: H021 oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H021
Description: H021 oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H021
Description: H021 oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H021
Description: H021 oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H021
Description: H021 oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H021
Description: H021 oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H021
Description: H021 oral tablet.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: H021 Placebo
Description: H021 placebo oral tablet.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: H021 Placebo
Description: H021 placebo oral tablet.
Study: NCT04653064

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control Cream
Description: Approximately 1 teaspoon of exfoliating skin scrub delivered approximately 5 minutes prior to pain tasks will coincide with verbal descriptors of the cream as one of no effect.
Study: NCT06450470

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic lens alone
Description: Therapeutic lens will be apposed on the patient's eye after crosslinking. Therapeutic lens will be maintained without interruption until the first postoperative visit (Day 2) when it will be removed by the investigator.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Therapeutic lens + amniotic membrane (Visio-AMTRIX)
Description: Amniotic membrane (Visio-AMTRIX) will be apposed under therapeutic lens on the patient's eye after crosslinking. Amniotic membrane and therapeutic lens will be maintained without interruption until the first postoperative visit (Day 2) when it will be removed by the investigator.
Study: NCT05966194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RRx-001
Description: RRx-001 for injection (4 mg or 8 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RRx-001
Description: RRx-001 for injection (4 mg or 8 mg)

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Intensity Modulated Radiation Therapy (IMRT)
Description: Intensity Modulated Radiation Therapy of up to 72 Gy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiation Therapy (IMRT)
Description: Intensity Modulated Radiation Therapy of up to 72 Gy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiation Therapy (IMRT)
Description: Intensity Modulated Radiation Therapy of up to 72 Gy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin for injection 100 mg/m2
Description: Cisplatin for injection 100 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin for injection 100 mg/m2
Description: Cisplatin for injection 100 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin for injection 100 mg/m2
Description: Cisplatin for injection 100 mg/m2
Study: NCT04630886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid injection
Description: subcutaneous injection of 50mg/ml TXA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine Epinephrine
Description: subcutaneous injection of 1% lidocaine mixed with 1:200,000 epinephrine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Epinephrine
Description: subcutaneous injection of 1% lidocaine mixed with 1:200,000 epinephrine
Study: NCT04165486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ION464
Description: ION464 will be administered by IT injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ION464
Description: ION464 will be administered by IT injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: ION464-matching placebo will be administered by IT injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: ION464-matching placebo will be administered by IT injection.
Study: NCT06426888

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental interventional group 1(scapular stabilization exercise therapy)
Description: Ball stabilization exercise: While standing close to the wall, the participant will be asked to position her affected hand on the ball and keep the ball from moving as disturbance will be applied in different directions.~Wall push up: While facing wall patient will be asked to place both hands on wall, shoulder width apart. He will be instruct to breath in, bend his elbows, lean into wall and hold this position for one second then breath out slowly push back until arms are straight again Wall slides~• Patient will be asked to lean his head, upper thorax and butts against the wall, place his hands and arms against the wall in high five position.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental :interventional group II (scapular mobilizations)
Description: Patient lies on unaffected side close to the edge of the treatment bench with hips and knees bent for stability.~Therapist will start by supporting the patient arm on his/her forearm so that shoulder is in maximally loose pack position.~Then he/she will grab on the scapula with both hands. One hand supports the scapula from cranial around the acromion and scapular spine and other hand from the caudal at the inferior angle of scapula.~Then both hands move the scapula cranially over the thorax into elevation and caudally into the depression, upward/downward rotation as well as retraction and protraction.
Study: NCT05896124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2mg CS0159
Description: Oral QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2mg CS0159
Description: Oral QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral QD
Study: NCT04570423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eflapegrastim
Description: Eflapegrastim supplied in prefilled, single-use syringes for SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eflapegrastim
Description: Eflapegrastim supplied in prefilled, single-use syringes for SC injection.
Study: NCT06304272

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Irrigating Traumatic Wound with Drinking Water
Description: Irrigating Traumatic Wound with Drinking Water and Normal Saline

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Irrigating Traumatic Wound with Drinking Water
Description: Irrigating Traumatic Wound with Drinking Water and Normal Saline
Study: NCT04570423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eflapegrastim
Description: Eflapegrastim supplied in prefilled, single-use syringes for SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eflapegrastim
Description: Eflapegrastim supplied in prefilled, single-use syringes for SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Chemotherapy agents may include doxorubicin, ifosfamide, docetaxel, CHOP regimen, etoposide, cyclophosphamide and vincristine which will be administered as per standard of care per the Primary Care physician's treatment plan.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Chemotherapy agents may include doxorubicin, ifosfamide, docetaxel, CHOP regimen, etoposide, cyclophosphamide and vincristine which will be administered as per standard of care per the Primary Care physician's treatment plan.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Chemotherapy agents may include doxorubicin, ifosfamide, docetaxel, CHOP regimen, etoposide, cyclophosphamide and vincristine which will be administered as per standard of care per the Primary Care physician's treatment plan.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Chemotherapy agents may include doxorubicin, ifosfamide, docetaxel, CHOP regimen, etoposide, cyclophosphamide and vincristine which will be administered as per standard of care per the Primary Care physician's treatment plan.
Study: NCT06019819

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: strengthening exercise
Description: Perform general physical training activities conducted in schools including upper limb forward elevation, lateral elevation, touching toes in standing and cervical range of motion, strengthening exercise will be performed for 3days a week for 4 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postural correction exercises
Description: Chin Tuck, Strengthening shoulder retractors, Stretching sternocleidomastoiD, Pectorals stretch For strengthening exercises 3 sets of 10 repetitions were performed with 6 seconds rest period between each set and a hold of 6 seconds. Stretching exercises will be performed in 3 sets of 10 repetitions ,30 seconds hold and 30 seconds rest period between each exercise. The exercises were performed 3days a week for 4 weeks.
Study: NCT05292183

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrical Stimulation
Description: We will use a computer randomized stimulation of specific areas in the amygdala while showing a computer randomized set of pictures.
Study: NCT06027892

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Two-fraction stereotactic radiotherapy
Description: Definitive prostate radiotherapy will be delivered to a dose biologically comparable to 40 Gy in 5 treatments, but in only 2 treatments

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Five-fraction stereotactic radiotherapy
Description: Definitive prostate radiotherapy will be delivered to a standard stereotactic dose of 40 Gy in 5 treatments
Study: NCT04949451

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein supplement
Description: Participants consume whey protein at the beginning of the eating period.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketogenic aid
Description: Participants consume ketogenic aid upon waking.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control group - time restricted feeding only
Description: Time restricted feeding.
Study: NCT06168799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ilofotase alfa
Description: After dilution of the concentrate, the investigational medicinal product will be administered by intravenous infusion for 1 hour at the same day before and after the surgery (Day 1)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: After dilution of the concentrate, the investigational medicinal product will be administered by intravenous infusion for 1 hour at the same day before and after the surgery (Day 1)